CAMBRIDGE

Bionomics Limited Announces Private Placement of up to $70.0 Million

Retrieved on: 
Freitag, Mai 31, 2024
Patient, Exchange, Food, BNC210, Exercise, PTSD, Sale, ADS, American depositary receipt, Prospectus, Research, SVB Securities, Public expenditure, Central nervous system, Security (finance)

The first tranche is an upfront payment to the Company of $7.5 million.

Key Points: 
  • The first tranche is an upfront payment to the Company of $7.5 million.
  • Assuming that the first, second and third tranches are consummated and exercised to the maximum extent, total gross proceeds from the private placement to the Company would be approximately $70.0 million.
  • The private placement is expected to close on or about June 3, 2024, subject to the satisfaction of customary closing conditions.
  • The Company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission registering the resale of the securities issued and issuable in the private placement.

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Retrieved on: 
Donnerstag, Mai 30, 2024
Patient, BIIB, Biogen, UZ Leuven, European Medicines Agency, Disease, Fever, ALS, Week, ITT, Civil service commission, European Commission, Spinal cord, MND, EMA, Pharming, Back pain, Brain, Mutation, AFL, Pain, Pharmaceutical industry

QALSODY is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Key Points: 
  • QALSODY is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
  • The primary efficacy endpoint was the change from baseline to Week 28 in the ALS Functional Ratings Scale-Revised total score.
  • “As a representative of the European ALS community, I am excited to enter a new evolution in the common fight against ALS.
  • QALSODY is also approved for use in the United States and Biogen is engaging with regulatory authorities in other regions.

Korro to Participate in Upcoming June Investor and Scientific Conferences

Retrieved on: 
Donnerstag, Mai 30, 2024
RNA, Longevity, Jefferies, Treatment, Therapy, RNA editing, Oligonucleotide, FAAN, Management

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences:

Key Points: 
  • CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences:
    Chief Executive Officer and President, Ram Aiyar, Ph.D., will present on Thursday, June 6, 2024, at 2:00 p.m.
  • Chief Financial Officer, Vineet Agarwal, will also be participating at the conference.
  • Dr. Krishnamurthy will also deliver a presentation titled “Edit the Message: Rewrite the Future” on June 20 at 1:30 p.m.
  • A live webcast of the Jefferies presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com.

Misleading COVID-19 headlines from mainstream sources did more harm on Facebook than fake news

Retrieved on: 
Donnerstag, Mai 30, 2024
COVID-19, Organization, News, URL, Management, University, Public, Death, Research, Social media, Vaccination, Professor, Vaccine hesitancy, Pharmaceutical industry

They show that misleading content from mainstream news sources — rather than outright misinformation or “fake news” — was the primary driver of vaccine hesitancy on Facebook.

Key Points: 
  • They show that misleading content from mainstream news sources — rather than outright misinformation or “fake news” — was the primary driver of vaccine hesitancy on Facebook.
  • “Misinformation has been correlated with many societal challenges, but there’s not a lot of research showing that exposure to misinformation actually causes harm,” explained Allen.
  • During the COVID-19 pandemic, for example, the spread of misinformation related to the virus and vaccine received significant public attention.
  • Researchers also asked a separate group of respondents to rate the headlines across various attributes, including plausibility and political leaning.

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

Retrieved on: 
Donnerstag, Mai 30, 2024
AGIO, Webcast, Conference, Agios Pharmaceuticals

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m.

Key Points: 
  • CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m.
  • ET.
  • A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com .
  • A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference

Retrieved on: 
Donnerstag, Mai 30, 2024
RNA, MBA, MD, Conference, Health

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 2024 Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024, at 7:30 a.m.

Key Points: 
  • CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 2024 Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024, at 7:30 a.m.
  • ET.
  • A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com .
  • A replay of this presentation will be archived and available on the site for a limited time following the event.

Vigil Neuroscience to Present in Upcoming June Investor Conferences

Retrieved on: 
Donnerstag, Mai 30, 2024
Conference, Microglia, Management

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management’s participation at two upcoming investor conferences.

Key Points: 
  • WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management’s participation at two upcoming investor conferences.
  • Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6th at 9:30 a.m. E.T.
  • Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11th at 10:40 a.m. E.T.
  • The live webcasts from the events will be available on the Company’s website on the “Events & Presentations” page in the “Investors” section.

Prime Medicine to Present at Upcoming Investor Conferences

Retrieved on: 
Donnerstag, Mai 30, 2024
News, Webcast, Conference

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer will present at two upcoming investor conferences:

Key Points: 
  • CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer will present at two upcoming investor conferences:
    Goldman Sachs 45th Annual Global Healthcare Conference: Fireside chat on Monday, June 10, 2024, at 2:00 p.m.
  • ET in Miami Beach, FL.
  • Live audio webcasts of both presentations will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com.
  • Replays of each webcast will be available on the Prime Medicine website for 90 days following the event.

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

Retrieved on: 
Donnerstag, Mai 30, 2024
Conference, Biotechnology

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, president of Beam, plans to participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m.

Key Points: 
  • CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, president of Beam, plans to participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m.
  • ET in New York City.
  • A live webcast will be available in the investor section of the company's website at www.beamtx.com , and will be archived for 60 days following the presentation.

BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel

Retrieved on: 
Donnerstag, Mai 30, 2024
Patient, CBER, Doctor of Philosophy, Research and development, Bayer, Food, Parkinson's disease, Regenerative Medicine Advanced Therapy, FDA, Therapy, Disease, Safety, Brain, Evaluation, Pharmaceutical industry

Berlin, Germany and Cambridge, MA, USA, May 30, 2024 (GLOBE NEWSWIRE) -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today that BlueRock’s investigational cell therapy bemdaneprocel for the treatment of Parkinson’s disease has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Berlin, Germany and Cambridge, MA, USA, May 30, 2024 (GLOBE NEWSWIRE) -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today that BlueRock’s investigational cell therapy bemdaneprocel for the treatment of Parkinson’s disease has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA).
  • “Now with this RMAT designation in hand, we look forward to closely collaborating with the FDA to ready this program for phase II clinical studies.”
    Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating Parkinson’s disease.
  • Phase I clinical trial data announced in March demonstrated that at 18 months it was well tolerated with no major safety issues.
  • Investigational therapies that receive RMAT designation are eligible to receive expedited development review and development planning guidance from senior CBER managers.